Clinical Trials Logo
  1. Home
  2. Biological Availability
  3. NCT01853800
  4. Details
NCT01853800 Clinical Trial

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

Biological Availability Clinical Trial

Official title:
Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare 10 mg of an Oral Suspension of Rivaroxaban Under Fasting (2 Different Batches) and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01853800
Other study ID # 16886
Secondary ID 2013-001720-19
Status Completed
Phase Phase 1
First received May 13, 2013
Last updated January 20, 2017
Start date May 2013
Est. completion date August 2013

Study information
Verified date January 2017
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders. Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels. Excessive coagulation activity can occur in children as well, and rivaroxaban is therefore being developed for the treatment of thromboembolic events in children and adolescents. As small children are often unable to swallow tablets, an oral suspension (mixture of a liquid containing finely distributed solids) has been developed which allows dosing according to body weight. The objective of this trial is to compare the bioavailability (proportion of a substance that remains available unchanged in the blood circulation) of a rivaroxaban oral solution with that of the rivaroxaban tablet approved for treatment. In order to evaluate the potential influence of food, the oral suspension containing 20 mg rivaroxaban will be taken after consuming food. In addition, the pharmacokinetics (concentrations of the drug and breakdown products (metabolites) in blood), safety and tolerability will be assessed.

Recruitment information / eligibility
Status Completed
Enrollment 14
Est. completion date August 2013
Est. primary completion date July 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Healthy male subjects

- Age: 18 to 55 years (inclusive) at the first screening examination

Exclusion Criteria:

- Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal

- Known coagulation disorders (eg von Willebrand's disease, hemophilia)

- Known disorders with increased bleeding risk (eg periodontosis, hemorrhoids, acute gastritis, peptic ulcer)

- Known sensitivity to common causes of bleeding (eg nasal)

- Regular use of medicines

- Clinically relevant findings in the ECG (electrocardiogram) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QTc-interval over 450 msec

- Clinically relevant findings in the physical examination

- Clinically relevant deviations of the screened laboratory parameters from reference ranges

- Participation in another clinical study during the preceding 3 months (Last Treatment from previous study to First Treatment of new study)

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Rivaroxaban (Xarelto, BAY59-7939)

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
Bayer Janssen Research & Development, LLC

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Area Under the Concentration Versus Time Curve From Zero to Infinity After a Single Dose (AUC) 0-72 hours
Primary Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose (AUC/D) 0-72 hours
Primary Maximum Observed Drug Concentration in Measured Matrix After a Single Dose (Cmax) 0-72 hours
Primary Maximum Observed Drug Concentration in Measured Matrix Divided by Dose (Cmax/D) 0-72 hours
Secondary Area Under the Concentration Versus Time Curve From Zero to Infinity Divided by Dose per Kilogram Body Weight (AUC,norm) 0-72 hours
Secondary Area Under the Concentration Versus Time Curve From Zero to Last Quantifiable Concentration [AUC(0tlast)] 0-72 hours
Secondary Maximum Observed Drug Concentration Divided by Dose per Kilogram Body Weight (Cmax,norm) 0-72 hours
Secondary Mean Residence Time (MRT) 0-72 hours
Secondary Maximum Observed Drug Concentration Divided by Drug Concentration at 24 hours (Cmax/C24h) 0-72 hours
Secondary Time to Reach Maximum Observed Drug Concentration (tmax) 0-72 hours
Secondary Terminal Half Life (t1/2) 0-72 hours
See also
  Status Clinical Trial Phase
Completed NCT05544786 - Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants. Phase 1
Completed NCT04744233 - Bioavailability of Carotenoids From Orange Juice in a Cross-over Study in Healthy Subjects. N/A
Completed NCT05561075 - Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form (BIOPTERO) N/A
Completed NCT03873909 - Bioavailability of Carotenoids Present in Mamey Sapote (Pouteria Sapota (Jacq.) H. E. Moore & Stearn) Fruit N/A
Completed NCT03353857 - Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam Phase 1
Completed NCT05121506 - A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults Phase 1
Completed NCT01267201 - A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form Phase 1
Completed NCT02538393 - Relative Bioavailability of Sorafenib Tablet for Oral Suspension Phase 1
Completed NCT05116982 - Effect of Three Silicon Based Food Supplements on the Urinary Excretion of Aluminum and Other Metals (SILIAL) N/A
Completed NCT04207372 - Protein Digestibility of Whey and Zein. N/A
Completed NCT00714584 - Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers Phase 1
Completed NCT04876261 - Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements N/A
Completed NCT03886597 - Nutritional Intervention With Table Olives in Healthy Volunteers Phase 1/Phase 2
Completed NCT06289140 - Oral Bioavailability of a New Formulation of Pterostilbene Cocrystal in Comparison With Its Free Form (BIOPTERO2) N/A
Completed NCT05439408 - Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions Phase 1
Completed NCT03951025 - Study of the Bioavailability of a Food Supplement Rich in Melatonin Administered Sublingually and Orally (MELATONIN) Phase 2
Completed NCT03984916 - Study of the Bioavailability of Three Hesperidin Extracts. N/A
Completed NCT02966704 - Stable Isotope Method to Assess Dietary Protein Quality N/A
Completed NCT02847117 - Bioavailability of the Microconstituents of Natural Chios Mastiha in Healthy Adults. N/A
Completed NCT03048110 - Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction Phase 1

External Links